Effects of nebulized antithrombin and heparin on inflammatory and coagulation alterations in an acute lung injury model in rats

Journal of Thrombosis and Haemostasis

Volumn 18, Issue 3, 2020, Pages 571-583

  Camprubí Rimblas, Marta ^a,b,c   Tantinyà, Neus ^a,c   Guillamat Prats, Raquel ^a,c   Bringué, Josep ^b,c   Puig, Ferranda ^a,c   Gómez, Maria Nieves ^a   Blanch, Lluís ^a,b,c,d   Artigas, Antonio ^a,b,c,d  

^a PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Critical Care Center   (Spain)

Author keywords

acute lung injury; antithrombin; heparin; inflammation; nebulization

Indexed keywords

ANTITHROMBIN III; FIBRINOGEN DEGRADATION PRODUCT; HEPARIN; HYDROCHLORIC ACID; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; TUMOR NECROSIS FACTOR; ANTICOAGULANT AGENT; ANTITHROMBIN;

ACUTE LUNG INJURY; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; LUNG PARENCHYMA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME; ANIMAL; BRONCHOALVEOLAR LAVAGE FLUID; FIBRINOLYSIS; LUNG;

ACUTE LUNG INJURY; ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION; BRONCHOALVEOLAR LAVAGE FLUID; FIBRINOLYSIS; HEPARIN; LUNG; RATS;

EID: 85076741739     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.14685     Document Type: Article

References (45)

1. Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med. 2017;377(19):1904-1905.
2. Villar J, Blanco J, Kacmarek RM. Current incidence and outcome of the acute respiratory distress syndrome. Curr Opin Crit Care. 2016;22(1):1-6.
3. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med. 2003;31(Suppl):S213-S220.
4. Warren BL, Eid A, Singer P, et al. KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286(15):1869-1878.
5. Eid A, Wiedermann CJ, Kinasewitz GT. Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSept-trial. Anesth Analg. 2008;107(5):1633-1638.
6. Murakami K, McGuire R, Cox RA, et al. Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock. 2002;18(3):236-241.
7. Juschten J, Tuinman PR, Juffermans NP, Dixon B, Levi M, Schultz MJ. Nebulized anticoagulants in lung injury in critically ill patients – an updated systematic review of preclinical and clinical studies. Ann Transl Med. 2017;5(22):444.
8. Enkhbaatar P, Cox RA, Traber LD, et al. Aerosolized anticoagulants ameliorate acute lung injury in sheep after exposure to burn and smoke inhalation. Crit Care Med. 2007;35(12):2805-2810.
9. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia – a review. Crit Care Med. 2006;34(3):871-877.
10. Okajima K, Uchiba M. The anti-inflammatory properties of antithrombin III: new therapeutic implications. Semin Thromb Hemost. 1998;24(1):27-32.
11. Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004;109(22):2698-2704.
12. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131(4):417-430.
13. Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest. 1984;74(2):341-350.
14. Damus PS, Rosenberg RD. Antithrombin-heparin cofactor. Meth Enzymol. 1976;45:653-669.
15. Hofstra JJ, Cornet AD, de Rooy BF, et al. Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats. Crit Care. 2009;13(5):R145.
16. Frantzeskaki F, Armaganidis A, Orfanos SE. Immunothrombosis in acute respiratory distress syndrome: cross talks between inflammation and coagulation. Respiration. 2017;93(3):212-225.
17. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407(6801):258-264.
18. Wiedermann CJ. Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis. Crit Care. 2006;10(1):209.
19. Hagiwara S, Iwasaka H, Matsumoto S, Noguchi T. High dose antithrombin III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats. Intensive Care Med. 2008;34(2):361-367.
20. Vuong TT, Reine TM, Sudworth A, Jenssen TG, Kolset SO. Syndecan-4 is a major syndecan in primary human endothelial cells in vitro, modulated by inflammatory stimuli and involved in wound healing. J Histochem Cytochem. 2015;63(4):280-292.
21. Okajima K. Regulation of inflammatory responses by natural anticoagulants. Immunol Rev. 2001;184:258-274.
22. Kaneider NC, Egger P, Dunzendorfer S, Wiedermann CJ. Syndecan-4 as antithrombin receptor of human neutrophils. Biochem Biophys Res Commun. 2001;287(1):42-46.
23. Camprubí-Rimblas M, Guillamat-Prats R, Lebouvier T, et al. Role of heparin in pulmonary cell populations in an in-vitro model of acute lung injury. Respir Res. 2017;18(1):89.
24. Capaldo CT, Nusrat A. Cytokine regulation of tight junctions. Biochim Biophys Acta. 2009;1788(4):864-871.
25. Puig F, Fuster G, Adda M, et al. Barrier-protective effects of activated protein C in human alveolar epithelial cells. PLoS ONE. 2013;8(2):e56965.
26. Ware LB. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med. 2006;27(4):337-349.
27. Puig F, Herrero R, Guillamat-Prats R, et al. A new experimental model of acid- and endotoxin-induced acute lung injury in rats. Am J Physiol Lung Cell Mol Physiol. 2016;311(2):L229-L237.
28. Chimenti L, Camprubí-Rimblas M, Guillamat-Prats R, et al. Nebulized heparin attenuates pulmonary coagulopathy and inflammation through alveolar macrophages in a rat model of acute lung injury. Thromb Haemost. 2017;117(11):2125-2134.
29. Bastarache JA, Sebag SC, Clune JK, et al. Low levels of tissue factor lead to alveolar haemorrhage, potentiating murine acute lung injury and oxidative stress. Thorax. 2012;67(12):1032-1039.
30. Choi G, Hofstra JJ, Roelofs JJ, et al. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med. 2008;36(1):204-210.
31. Li Y, Sun JF, Cui X, et al. The effect of heparin administration in animal models of sepsis: a prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies. Crit Care Med. 2011;39(5):1104-1112.
32. Hofstra JJ, Vlaar AP, Cornet AD, et al. Nebulized anticoagulants limit pulmonary coagulopathy, but not inflammation, in a model of experimental lung injury. J Aerosol Med Pulm Drug Deliv. 2010;23(2):105-111.
33. Cornet AD, Hofstra JJ, Vlaar AP, et al. Nebulized anticoagulants limit coagulopathy but not inflammation in pseudomonas aeruginosa-induced pneumonia in rats. Shock. 2011;36(4):417-423.
34. Rehberg S, Yamamoto Y, Sousse LE, et al. Antithrombin attenuates vascular leakage via inhibiting neutrophil activation in acute lung injury. Crit Care Med. 2013;41(12):e439-e446.
35. Ning F, Wang X, Shang L, et al. Low molecular weight heparin may prevent acute lung injury induced by sepsis in rats. Gene. 2015;557(1):88-91.
36. Liu Y, Beyer A, Aebersold R. On the dependency of cellular protein levels on mRNA abundance. Cell. 2016;165(3):535-550.
37. Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth. 2014;58(5):515-523.
38. Smith SA, Travers RJ, Morrissey JH. How it all starts: initiation of the clotting cascade. Crit Rev Biochem Mol Biol. 2015;50(4):326-336.
39. Rehberg S, Yamamoto Y, Sousse LE, et al. Advantages and pitfalls of combining intravenous antithrombin with nebulized heparin and tissue plasminogen activator in acute respiratory distress syndrome. J Trauma Acute Care Surg. 2014;76(1):126-133.
40. Gando S. Tissue factor in trauma and organ dysfunction. Semin Thromb Hemost. 2006;32(1):48-53.
41. Ozolina A, Sarkele M, Sabelnikovs O, et al. Activation of coagulation and fibrinolysis in acute respiratory distress syndrome: a prospective pilot study. Front Med. 2016;3:64.
42. Johnston LK, Rims CR, Gill SE, McGuire JK, Manicone AM. Pulmonary macrophage subpopulations in the induction and resolution of acute lung injury. Am J Respir Cell Mol Biol. 2012;47(4):417-426.
43. Aggarwal NR, King LS, D’Alessio FR. Diverse macrophage populations mediate acute lung inflammation and resolution. Am J Physiol Lung Cell Mol Physiol. 2014;306(8):L709-L725.
44. Herold S, Mayer K, Lohmeyer J. Acute lung injury: how macrophages orchestrate resolution of inflammation and tissue repair. Front Immunol. 2011;2:65.
45. Juschten J, Ingelse SA, Maas MAW, et al. Antithrombin plus alpha-1 protease inhibitor does not affect coagulation and inflammation in two murine models of acute lung injury. Intensive Care Med Exp. 2019;7(Suppl 1):36.